Abstract 115P
Background
Colorectal cancer is in fourth place due to mortality worldwide. In order to improve the diagnosis of colorectal cancer, immunohistochemical studies are becoming increasingly popular. The available literature contains a number of publications devoted to the study of the prognostic value of the expression of various biomarkers. However, the value of expression levels of the proliferation marker Ki-67 in colorectal cancer remains poorly understood. In this regard, the purpose of our study was to study the clinical significance of the expression of Ki-67 as a prognostic factor in patients with colorectal cancer.
Methods
To study the clinical significance of the expression of Ki-67 as a prognostic factor in patients with colorectal cancer, we examined 201 patients with colorectal cancer who were undergoing surgical treatment in combination with chemotherapy.
Results
A study of the proliferative activity of tumor glandular epithelial cells using patient Ki-67 proliferation marker showed that low or medium expression level (≤ 30%) was observed in 138 (68.9%) patients, while high (> 30%) - in 63 patients (31.1%). Binary logistic regression made it possible to establish links between the expression level of Ki-67 and the tumor stage, the presence of metastases in regional lymph nodes, the presence of distant metastases and the degree of tumor differentiation. In particular, patients with stage II, III, and IV stages of cancer had a higher chance of having a high level of Ki-67 expression than patients with stage I disease — 2.63, 3.16, and 3.97 times, respectively. The presence of 4 or more regional lymph nodes (N2) was accompanied by higher chances (6.6 times) to have a high level of expression of Ki-67, and the presence of distant metastases (M1) - by 1.92 times. Patients with low-differentiated cancer had a 5.1- times higher chance of being in the group with a high level of Ki-67 expression than patients with highly differentiated cancer.
Conclusions
The results of the research on finding the most informative and effective methods for predicting and diagnosing colorectal cancer among residents of the studied region will allow developing and introducing methods for complex primary and secondary prevention.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience
Presenter: Yvonne Ang
Session: Poster display session
Resources:
Abstract
498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study
Presenter: Shang-gin Wu
Session: Poster display session
Resources:
Abstract
501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Presenter: Xin Gao
Session: Poster display session
Resources:
Abstract
502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
Presenter: Masaki Kanazu
Session: Poster display session
Resources:
Abstract
482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo De Marinis
Session: Poster display session
Resources:
Abstract
483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
Presenter: Rafael Rosell
Session: Poster display session
Resources:
Abstract
484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
Presenter: Maya Gottfried
Session: Poster display session
Resources:
Abstract
491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
Presenter: Chia-I Shen
Session: Poster display session
Resources:
Abstract
510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract
496P - Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs
Presenter: Taira Ninomaru
Session: Poster display session
Resources:
Abstract